Austin Henry - Academia.edu (original) (raw)

Papers by Austin Henry

Research paper thumbnail of Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease ( <scp>NAFLD</scp> )

Alimentary Pharmacology & Therapeutics, Nov 15, 2022

SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adult... more SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known.AimTo investigate association between LTPA and reduction in all‐cause mortality among adults with NAFLD.MethodsWe used NHANES (1999–2006) self‐reported PA data for adults (≥40 years) with mortality follow‐up through December 31, 2015. US‐Fatty Liver Index in absence of secondary causes identified NAFLD. Moderate and vigorous LTPA were calculated by the 2018 PA Guidelines for Americans.ResultsNAFLD prevalence among 5211 adults (46.2% male; 75.8% white; mean age 53.2 years) was 32.7%. Adults with NAFLD were less likely to report the recommended minimal PA (≥ 150 min/week, 55.5% vs 64.8%) or highly active PA (≥300 min/week, 39.2% vs 48.5%) compared to adults without NAFLD. Over a median follow‐up of 12.3 years, 355 deaths among adults with NAFLD and 510 deaths among adults without NAFLD were registered. In the metabolic comorbidities‐adjusted model, adults with NAFLD who reported ≥50% of their total PA as vigorous activity had a 56% reduction in all‐cause mortality risk (HR:0.44, 95%CI: 0.25–0.76) and cancer‐specific mortality risk (HR: 0.21, 0.06–0.66) but not cardiac‐specific mortality (p &gt; 0.05) compared to adults with NAFLD who did not report any LTPA. This association remained significant even among adults with NAFLD who met the recommended minimal PA, among adults with NAFLD who reported any LTPA, and among adults with NAFLD who had metabolic abnormalities and in sensitivity analysis.ConclusionsEngaging in vigorous activity is beneficial for adults with NAFLD ‐ especially those with metabolic abnormalities.

Research paper thumbnail of The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Hepatology, Jan 3, 2023

The estimated prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide is approximately ... more The estimated prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide is approximately 25%. However, the real prevalence of NAFLD and the associated disorders is unknown mainly because reliable and applicable diagnostic tests are lacking. This is further complicated by the lack of consensus on the terminology of different How to cite this article: Araújo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis: What we need in the future. Liver

Research paper thumbnail of Editorial: let's get physical—long‐term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease. Authors' reply

Alimentary Pharmacology & Therapeutics, Feb 23, 2023

Research paper thumbnail of Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)

Alimentary Pharmacology & Therapeutics

SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adult... more SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known.AimTo investigate association between LTPA and reduction in all‐cause mortality among adults with NAFLD.MethodsWe used NHANES (1999–2006) self‐reported PA data for adults (≥40 years) with mortality follow‐up through December 31, 2015. US‐Fatty Liver Index in absence of secondary causes identified NAFLD. Moderate and vigorous LTPA were calculated by the 2018 PA Guidelines for Americans.ResultsNAFLD prevalence among 5211 adults (46.2% male; 75.8% white; mean age 53.2 years) was 32.7%. Adults with NAFLD were less likely to report the recommended minimal PA (≥ 150 min/week, 55.5% vs 64.8%) or highly active PA (≥300 min/week, 39.2% vs 48.5%) compared to adults without NAFLD. Over a median follow‐up of 12.3 years, 355 deaths among adults with NAFLD and 510 deaths among adults without NAFLD were registered. In the metabolic comorbidities‐adjusted model, adults with NAF...

Research paper thumbnail of Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes

Hepatology (Baltimore, Md.), Jul 28, 2015

NAFLD is a major cause of liver disease worldwide. We estimated the global prevalence, incidence,... more NAFLD is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression and outcomes of NAFLD and NASH. Pubmed/MEDLINE were searched from 1989-2015 for terms involving epidemiology and progression of NAFLD. selected groups (only morbidly obese or diabetics or pediatric), no data on alcohol consumption or other liver diseases. Incidence of HCC, cirrhosis, overall mortality and liver-related mortality were determined. NASH required histologic criteria. All studies were reviewed by 3 independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication and study population. We used random-effects models to provide point estimates (95% CI) of prevalence, incidence, mortality and incidence rate ratios, and meta-regression with sub-group analysis to account for heterogeneity. Out of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (22.10-28.65) with hi...

Research paper thumbnail of The most recent and in-depth meta-analytic assessment of the global epidemiology of non-alcoholic fatty liver disease (NAFLD)

Research paper thumbnail of Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease ( <scp>NAFLD</scp> )

Alimentary Pharmacology & Therapeutics, Nov 15, 2022

SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adult... more SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known.AimTo investigate association between LTPA and reduction in all‐cause mortality among adults with NAFLD.MethodsWe used NHANES (1999–2006) self‐reported PA data for adults (≥40 years) with mortality follow‐up through December 31, 2015. US‐Fatty Liver Index in absence of secondary causes identified NAFLD. Moderate and vigorous LTPA were calculated by the 2018 PA Guidelines for Americans.ResultsNAFLD prevalence among 5211 adults (46.2% male; 75.8% white; mean age 53.2 years) was 32.7%. Adults with NAFLD were less likely to report the recommended minimal PA (≥ 150 min/week, 55.5% vs 64.8%) or highly active PA (≥300 min/week, 39.2% vs 48.5%) compared to adults without NAFLD. Over a median follow‐up of 12.3 years, 355 deaths among adults with NAFLD and 510 deaths among adults without NAFLD were registered. In the metabolic comorbidities‐adjusted model, adults with NAFLD who reported ≥50% of their total PA as vigorous activity had a 56% reduction in all‐cause mortality risk (HR:0.44, 95%CI: 0.25–0.76) and cancer‐specific mortality risk (HR: 0.21, 0.06–0.66) but not cardiac‐specific mortality (p &gt; 0.05) compared to adults with NAFLD who did not report any LTPA. This association remained significant even among adults with NAFLD who met the recommended minimal PA, among adults with NAFLD who reported any LTPA, and among adults with NAFLD who had metabolic abnormalities and in sensitivity analysis.ConclusionsEngaging in vigorous activity is beneficial for adults with NAFLD ‐ especially those with metabolic abnormalities.

Research paper thumbnail of The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Hepatology, Jan 3, 2023

The estimated prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide is approximately ... more The estimated prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide is approximately 25%. However, the real prevalence of NAFLD and the associated disorders is unknown mainly because reliable and applicable diagnostic tests are lacking. This is further complicated by the lack of consensus on the terminology of different How to cite this article: Araújo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis: What we need in the future. Liver

Research paper thumbnail of Editorial: let's get physical—long‐term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease. Authors' reply

Alimentary Pharmacology & Therapeutics, Feb 23, 2023

Research paper thumbnail of Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)

Alimentary Pharmacology & Therapeutics

SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adult... more SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known.AimTo investigate association between LTPA and reduction in all‐cause mortality among adults with NAFLD.MethodsWe used NHANES (1999–2006) self‐reported PA data for adults (≥40 years) with mortality follow‐up through December 31, 2015. US‐Fatty Liver Index in absence of secondary causes identified NAFLD. Moderate and vigorous LTPA were calculated by the 2018 PA Guidelines for Americans.ResultsNAFLD prevalence among 5211 adults (46.2% male; 75.8% white; mean age 53.2 years) was 32.7%. Adults with NAFLD were less likely to report the recommended minimal PA (≥ 150 min/week, 55.5% vs 64.8%) or highly active PA (≥300 min/week, 39.2% vs 48.5%) compared to adults without NAFLD. Over a median follow‐up of 12.3 years, 355 deaths among adults with NAFLD and 510 deaths among adults without NAFLD were registered. In the metabolic comorbidities‐adjusted model, adults with NAF...

Research paper thumbnail of Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes

Hepatology (Baltimore, Md.), Jul 28, 2015

NAFLD is a major cause of liver disease worldwide. We estimated the global prevalence, incidence,... more NAFLD is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression and outcomes of NAFLD and NASH. Pubmed/MEDLINE were searched from 1989-2015 for terms involving epidemiology and progression of NAFLD. selected groups (only morbidly obese or diabetics or pediatric), no data on alcohol consumption or other liver diseases. Incidence of HCC, cirrhosis, overall mortality and liver-related mortality were determined. NASH required histologic criteria. All studies were reviewed by 3 independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication and study population. We used random-effects models to provide point estimates (95% CI) of prevalence, incidence, mortality and incidence rate ratios, and meta-regression with sub-group analysis to account for heterogeneity. Out of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (22.10-28.65) with hi...

Research paper thumbnail of The most recent and in-depth meta-analytic assessment of the global epidemiology of non-alcoholic fatty liver disease (NAFLD)